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Hepatitis B and C infections are prevalent among HIV-infected individuals with diﬀerent epidemiologic proﬁles, modes of
transmission, natural histories, and treatments. Southeast Asian countries are classiﬁed as “highly prevalent zones,” with a rate of
hepatitis B and C coinfection in people living with HIV/AIDS of approximately 3.2–11%. Majority of hepatitis B coinfection is of
genotype C. Most of the patients infected with hepatitis C in Thailand have genotype 3 which is signiﬁcantly related to intravenous
drug use whereas, in Vietnam, it is genotype 6. The options for antiretroviral drugs are limited and rely on global funds and
research facilities. Only HBV treatment is available for free through the national health scheme. Screening tests for HBV and HCV
prior to commencing antiretroviral treatment are low. Insuﬃcient concern on hepatitis-virus-related liver malignancy and long-
term hepatic morbidities is noted. Cost-eﬀective HCV treatment can be incorporated into the national health program for those
who need it by utilizing data obtained from clinical research studies. For example, patients infected with HCV genotype 2/3 with
a certain IL-28B polymorphism can be treated with a shorter course of interferon and ribavirin which can also help reduce costs.
1.Introduction
Most countries in Southeast Asia currently have limited
resources in providing universal coverage for HIV treatment
and care. Since the start of the global AIDS epidemic,
Thailand has become the only country within this region
with a high prevalence of HIV infection (>1%). In 2009,
the HIV prevalence has decreased to 2.3 million because
of the HIV prevention campaigns. These HIV prevention
campaignsfocusedonpromotingtheuseofcondomsamong
commercial sex workers and their clients which achieved
>90–95% success in preventing HIV transmission. Another
campaignknownasthepreventionofmother-to-childtrans-
mission (PMTCT) was also successful. However, in recent
years, the rates of new HIV infection have increased among
hard-to-reach groups such as the men having sex with men
(MSM), injection drug users (IDUs), and adolescents. It
has been shown that only 20–30% of sexually active young
people used condoms consistently. Furthermore, these HIV-
infected high risk groups have sexually transmitted hepatitis
infection, especially HCV.
Antiretroviral drugs are provided through the national
health schemes and international funding agencies such as
the Global Fund and PEPFAR. These antiretroviral therapy
(ART) programs provide ﬁnancial support for ARV protocol
development, professional health care training, drug supply
chain management, formation of a laboratory network,
monitoring and evaluation, and other needs requested by
the multisector and various people living with HIV/AIDS
(PLWHA) groups. The program has scaled up but mostly
lacks local leadership, comprehensive training, and coordi-
nation to achieve and sustain the success of the program.
Furthermore, patients coinfected with hepatitis are currently
being ignored. Screening and treatment for hepatitis coin-
fection should be included in the national policy to reduce
problems in the future.2 AIDS Research and Treatment
2. Epidemiology of HBV and HCV Coinfection
It has been documented that HBV infection in the general
population is high (>8%) in many countries from the
Southeast Asia region [1–4]. Reports showing lower infec-
tion rates of 3.2–6% from Brunei Darussalam, Indonesia,
Philippines, and Thailand [5–9]a r eb a s e do nc a s e si n f e c t e d
through vertical transmission. In tertiary care settings, HBV
infectioninHIV-infectedpopulationwasapproximately8.7–
11% [10–14]. MSMs and IDUs are at a higher risk of being
infected with HBV and HIV. However, the infection rate
of HBV in PLWHA is not that much diﬀerent compared
to the general population of which majority are infected
perinatally.ThemostcommonHBVgenotypesareC[15–17]
and B [18, 19] followed by A. The most common genotypes
found among migrants living in Thailand are C (86%) and
B (11.6%) [20]. The prevalences of HBsAg among migrants
from Cambodia, Laos, and Myanmar living in Thailand were
10.8%, 6.9%, and 9.7%, respectively [20]. In the last 10
years, chronic perinatal infection has decreased when the
national program expanded its immunization protocol to
include HBV vaccination in all children. Even though the
HBV subtypes of the surface antigen [15, 18, 21]r e p o r t e d
are adr and adw, this is not clinically signiﬁcant because the
HBV vaccine of either adw or ayw subtype can yield anti-a
which is protective against crossinfection with other HBsAg
subtypes as well [22].
In contrast to HBV, HCV co-infection is moderately
high in PLWHA, especially among IDUs and MSMs. If HIV
prevalence in IDUs is high, eventually HCV co-infection will
become a major problem as currently seen in Thailand and
Vietnam [23]. Among PLWHA, it has been estimated that
approximately 5–40% have contacted HIV from injecting
drugs.InThailandandVietnam,atleast50%ofIDUsareliv-
ing with HIV/AIDS, and about 90–95% have also contracted
HCV. The estimated prevalence of HCV/HIV co-infection is
7.2–10.1%[10,11,14,24,25].UnlikeThailandandVietnam,
in the Philippines, 83–89% of IDUs are infected with HCV
whereas only 0.34% are infected with HIV. Hence, the preva-
lence of HCV/HIV co-infection is low [26]. Factors such
as males [10, 27] and IDUs are at higher risk of becoming
infected with HCV and HIV. Among the general population,
the most common genotypes of HCV in Thailand, Vietnam,
and Indonesia are 3a (70%), 6a (32.5%), and 1b (47.3%),
respectively [25, 28, 29]. However, in HIV-infected individ-
uals, genotype 1 is increasingly found [27]. The prevalence
of HIV-HBV-HCV triple infection is rare (0.4%) but can
be found among IDUs and MSMs [11]. The predominant
HCV genotypes detected in migrants from Cambodia, Laos,
and Myanmar living in Thailand were 1a, 1b, 3, and 6,
respectively.However,thisdatamaynotaccuratelyreﬂectthe
real HCV genotypes among these groups of people because
f e ws a m p l e sw e r ec o l l e c t e df r o mt h a ts t u d y[ 30].
3.Approach in Diagnosing HBV or HCV among
HIV-InfectedPatients
Many individuals infected with HBV at birth or during
early childhood and subsequently infected with HIV have
asymptomatic HBV chronic infection with or without ami-
notransaminase elevation. Patients who develop acute hep-
atitis B during their adulthood will have abrupt and progres-
sive jaundice with GI symptoms such as nausea, abdominal
pain, ﬂatulence, and bloated abdomen. The general symp-
toms include fatigue, dizziness, weight loss, or anorexia. The
liver is usually not enlarged, and the cutaneous stigmata of
chronic liver disease is not detected unless the disease has
progressed to decompensated cirrhosis. Cirrhosis is more
common in patients with lower levels of ALT and CD4 com-
pared to those monoinfected with HBV [31, 32]. HIV-HBV
co-infected men are much more likely to die of liver-re-
lated causes compared to monoinfected HBV patients [33].
TheriskofHCCissomewhatincreasedinHIV-infectedindi-
viduals with low CD4 counts [34]. Patients with genotype C
have exhibited earlier progression of cirrhosis and HCC than
those with genotype B [17].
Similarly, patients co-infected with HCV and HIV have
asymptomatic acute HCV infection. It is also possible that
many IDUs co-infected with HCV and HIV may not have
reported their symptoms, and this may not necessary reﬂect
anaccurateaccountofHCVinfectionamongthesegroupsof
people. Usually, in non-IDUs, acute hepatitis C is detected in
PLWHAs currently on treatment and diagnosed with sexu-
ally transmitted infections (e.g., syphilis, gonorrhea) because
of elevated enzyme levels. HIV positive individuals with
acute HCV infection can develop chronic HCV infection.
In contrast to HBV, in HCV co-infected patients, disease
progression to liver cirrhosis and hepatocellular carcinoma
(HCC)occursveryquicklyandmayexistpriortoHCVtreat-
ment. As a result of this, physicians need to closely monitor
these patients, even those that have sustained viral response
to HCV treatment. Routine HBV and HCV screening are
not routinely performed at tertiary care setting. Many HIV
patients with undetectable HIV RNA and elevated liver
enzymes are screened for hepatitis and eventually found to
be co-infected with HBV [14, 35].
Currently, the national guidelines for antiretroviral ther-
apy inHIV-infectedadultsandadolescentsinmost countries
recommend HIV-infected persons to be screened for HBV
before initiating ART. The reason for this is because this
will help guide physicians in designing the patient’s HAART
regimen which should contain at least 2 antiretroviral drugs
with activity against both HIV and HBV, that is, tenofovir
plus lamivudine or tenofovir plus emtricitabine. The viral
hepatitis serology is widely available but not routinely used
to screen those patients most at risk such as IDUs and
MSMs. Tests for HBs antigen are recommended to all HIV-
infected patients, but recently, in actual practice, 55–69% of
HIV-infected adults were tested for hepatitis [12, 13, 36].
Asymptomatic chronic infected cases are not unmasked and
may continue to transmit the viruses through contaminated
blood and genital secretions. If HIV-infected people are
aware of the eﬀects of HBV and the accessibility of HBV
treatment, then the rate of HBV screening prior to ART
may improve. The results of HBV serologic proﬁles are
interpreted as mono-HBV infection (see Table 1). How-
ever, isolated positive core antibodies are more frequently
(20–30%) found in co-infected patients [37]c o m p a r e dAIDS Research and Treatment 3
Table 1: Findings and interpretations of HBV serologic markers.
HBs Ag Anti-HBs Anti-HBc Hbe Ag Interpretation
+ −−+ Chronic replicative phase or acute infection
+ − + − Chronic nonreplicative/carrier (DNA neg)
Flare up (DNA positive)
+ −−− Precore mutants
−− + −
Isolated core antibody
Recovery from acute infection
Occult infection (DNA positive)
− + −− Previously immunized with HBV vaccine
to those monoinfected with HBV, especially in advanced
immunocompromised [38], HCV co-infected cases [39–41],
or IDUs. The clinical signiﬁcance of having a positive anti-
HBc antibody is not well understood, but there is more
evidence indicating that people with this serologic ﬁnding
has an occult infection with frequent hepatic ﬂares [42]a n d
potential of transmitting the infection [43–46]. In certain
cases, some may have undetectable HBV DNA with isolated
core antibody [47, 48].
Since HBV/HIV co-infection is common, it is highly
recommended that in every HIV-infected individuals, sero-
logic screening tests for hepatitis B should include HBs
Ag, anti-HBs, and anti-HBc antibody. If all 3 serologic
tests are negative, then it is highly recommended that the
patients get a hepatitis B vaccine to prevent infection. If
an isolated core antibody is detected, then a conﬁrmatory
HBV-DNA or complete liver function workup is needed to
help guide the patients’ long-term care management. It
is not conclusive whether HIV-infected individuals with
isolated core antibody should get a Hepatitis B vaccine. The
vaccination may have a primary or an amnestic response
[37]. If HBs antigen is positive, then it is important to assess
whether the patient also has HBe Ag, anti-HBe antibody,
HBV-DNA and liver enzymes to rule out viral replication,
liver complications and whether treatment is needed.
Majority of patients presenting acute HBV infection will
have elevated levels of liver enzymes (ALT > AST with >10
times ULN). However, as for those currently infected with
HBV or have tested positive for HBs antigen, it is diﬃcult to
diﬀerentiate whether they are HBV carriers or have chronic
infection with low or nonreplicative phase. In healthy carri-
ers, HBV-DNA may not be detectable because of transient
viremia and therefore would require retesting. HBV-DNA
is somewhat useful but is too expensive for some countries
with limited resources. Certain places may not have access
to machines to detect HBV-DNA, and some patients may
not be able to aﬀord such diagnostic tests. In order to detect
and diﬀerentiate chronic active HBV patients from positive
serostatus for HBe Ag, physicians would need the patients’
medical history, risk behaviors or predisposing factors, and
physical ﬁndings such as stigmata of chronic liver.
L i v e re n z y m e sc a nb eu s e da sas u r r o g a t em a r k e rf o r
detecting hepatic necroinﬂammation, but its elevation may
also indicate a hepatic ﬂare from any causes including the
virus itself. Serum aminotransferase levels are less reliable in
determining whether the patient would need therapy or not.
Serum aminotransferase levels can be lower in patients co-
infected with HIV and HBV or within normal range in some
patients with signiﬁcant hepatic ﬁbrosis. Even though liver
pathology can speciﬁcally detect ﬁbrosis and necroinﬂam-
mation by using a scoring system; however, its procedure is
invasive, time-consuming and may not be sensitive if there
is bias in the way the samples are collected or assessed.
Assessing the extent of the underlying liver damage is
important because it will aﬀect the prognosis of the infection
as well as the choices for treatment. Another noninvasive test
known as the hepatic elastography (Fibroscan) can be used
to measure the liver’s stiﬀness or evaluate hepatic ﬁbrosis.
The results from the Fibroscan can guide treatment and
care but may not be possible in resource-limited settings.
Some of the limitations of the ﬁbroscan are its inability to
accurately predict the degree of injury seen on a liver biopsy
or subsequent clinical events. Close monitoring is necessary
to detect early cases.
In regards to HCV co-infection, the national guidelines
recommend to screen for anti-HCV antibody before initi-
ating ART in HIV-infected adults exhibiting symptoms or
those with risk factors such as intravenous drug use. The
treatment cost for HCV is extremely expensive and is not
covered by the national health schemes. Patients with HCV
who need treatment must pay for their own treatment.
Aside from that, the national health schemes do not provide
free diagnostic tests for HCV genotype and HCVRNA
load. At the present, in majority of the countries, there is
insuﬃcient epidemiological data on HIV/HCV co-infection.
Hence this may be one of the reasons why the national health
schemes will not oﬀer free HCV testing in HIV-infected
individuals. According to the physicians who have done anti-
HCV tests in their HIV-infected patients, there is a high
prevalence of HCV co-infection. This result indicates that
an appointed committee should include HCV tests in the
national guidelines for HIV-infected patients.
It is possible to use tests to detect for anti-HCV antibody
to screen those groups at risk for acquiring the infection.
However, it is important to note that anti-HCV serocon-
version occurs much slower in HIV-infected patients, and
it is still possible to have anti-HCV negative results despite
ongoing viral replication for a year [49]. Currently, HCV
antibody tests cost around 6–9 USD. In a resource-limited
setting, this cost is aﬀordable yet it is not included in the
national health care program. This test can be used to screen
and diagnose HCV in HIV-infected patients even though4 AIDS Research and Treatment
it may not be perfect. It can be used in clinical settings
or as requested. In most of the cases, there are no or
very little clinical symptoms as seen in people with acute
HCV infection. Therefore, acute HCV infection is deﬁned
as having detectable HCV-RNA in the ﬁrst 6 months after
infection. Transaminase levels can also be used to accurately
detect acute HCV infection. Elevated levels of alanine
transaminase (ALT) are more sensitive in detecting acute
HCV when compared to anti-HCV antibody tests. Tests to
detectHCV-RNAareusedtodeterminethevirus’sreplicative
state. Hence results from HCV-RNA tests can detect early
infection better than the antibody tests and are usually used
to exclude false positive results obtained from the serologic
tests when the patients have disclosed not having any risk
behaviors. Sometimes it is also used to determine whether
the result from the serology test is a false positive or not.
PastresolvedHCVinfectionmayyieldfalsepositiveresultsin
the serology test. HIV positive individuals who need to start
antiviral treatment should be screened for HCV by using
the HCV-RNA tests and monitored regularly [50]. Chronic
hepatitis C infection is deﬁned as having ongoing viral
replication for more than 6 months. Without the patient’s
past hepatitis C test results, it is diﬃcult to determine the
HCV status of the patient based only on the patient’s history,
current physical and laboratory examinations. It is very
diﬃcult to distinguish between acute and chronic infection
because ﬂares during chronic hepatitis C may mimic acute
infection.
Genotyping should be done in every case who will need
HCV treatment because this will help guide the physician
in determining the length of treatment, predict treatment
response and prognosis of HCV (see Figure 1). However,
if genotyping tests are not available, then physicians from
resource-limited setting can use regional epidemiological
data to determine the subtype of HCV. As for those patients
not on HCV treatment due to no indication, treatment
intolerability or failure and drug availability, it is important
to continue to monitor and assess the progression of the
disease. Liver enzymes should regularly be checked every 3
months and repeated if there are signiﬁcant elevations. The
degree of histologic injury is a better predictor of subse-
quent clinical events than is the degree of elevated serum
aminotransferase levels, genotype, or viral load. The result
of the Fibroscan can support the physician’s decision to start
or defer treatment with a higher level of conﬁdence. CD4
cell count appears to be a good predictor for spontaneous
clearance [51]. Antiretroviral treatment may help to control
HCV if HCV treatment is not provided. Thrombocytopenia
and reversed albumin/globulin ratio can be detected in cases
with progressive liver cirrhosis in patients with hepatitis
C. Also, serological markers correlated with stages of liver
ﬁbrosis can be used with indices obtained from routine
blood tests to determine the function of the liver (e.g., APRI
(aspartate aminotransferase [AST]-to-platelet ratio index)
and Fib-4 (age, AST, platelets, and ALT level)). Alpha feto-
protein (AFP), a tumor marker for hepatocarcinoma, can
help interpret liver images whereas pathology can conﬁrm
the stage of the disease. Screening for hepatocarcinoma
shouldincludeultrasoundoftheliverandserumAFPshould
be performed every 6 months for all chronic hepatitis B
and C patients with cirrhosis. However, according to the
systematic reviews, AFP is not considered sensitive (73.5%)
[52, 53] and has no existing correlations in hepatocarcinoma
[54].Thisservesasawarningsignthatmoreneedstobedone
topreventthetransmissionofthevirusaswellasincreasethe
community’s awareness of comorbidity among hepatitis co-
infected patients.
In conclusion, routine screening using serologic tests for
hepatitis B and C is beneﬁcial for the patient to determine
when to start treatment or those who cannot aﬀord such
care to closely monitor the disease progression and compli-
cations. The use of stavudine, didanosine, and nevirapine,
whichareunfriendlytotheliver,shouldbeusedwithcaution
because it can lead to liver toxicities. For public health
concerns, this will also help reduce the risk of transmission if
treatment is provided and reduce risk behaviors. As for those
at risk of acquiring hepatitis such as immunocompromised
patients, physicians can recommend HBV vaccinations. It is
highly recommended that in resource-limited settings where
there is a high prevalence of hepatitis, HBV and HCV should
be screened in HIV-infected patients prior to ART.
4. Management of CoinfectedPatients
Recently, the international HIV treatment guidelines 2011
recommend that antiretroviral therapy should be started in
all HBV/HIV co-infected adolescents and adults who require
treatment for chronic active hepatitis B irrespective of their
CD4 cell counts. According to these new guidelines, all HIV-
infected individuals with CD4 ≤ 350 cells/μL are required to
startantiretroviraltherapyregardlessofsymptoms.However,
in the middle of 2011, there is evidence that this is not imple-
mented throughout the region. Therefore, it is important
to assess the treatment rates in cases with CD4 of 200–350
cell/μL to ensure treatment coverage and care among these
people in order to reduce opportunistic infections in severely
immunocompromised patients. Some nucleoside/nucleotide
analogs for HIV treatment are eﬀective to both HIV and
HBV and therefore can be used to treat HIV/HBV co-
infected patients. Furthermore, the results from the study on
Tenofovir in HBV Coinfection (TICO) which was conducted
in Thailand showed that a combination of tenofovir and
emtricitabine or lamivudine was better than using only
tenofovir [55, 56]. There was an increased loss of HBeAg
when a longer follow-up period was implemented to assess
HBVtreatmentoutcome.Hepaticﬂareswereobservedin19–
25% of the patients without any severe complications. Inter-
estingly, long-term use of tenofovir in HIV/HBV co-infected
patients may prevent disease progression to end-stage liver
disease in the Thai population, by slowing or reversing liver
ﬁbrosis. Currently, the Thai national guideline recommends
using tenofovir with either lamivudine or emtricitabine
for any HBV co-infected individuals regardless of their
baseline CD4+ T-cell count. Since HBV treatment is cheap
(approximately 55 USD/mo. for tenofovir plus lamivudine
and 70 USD/mo. for tenofovir plus emtricitabine), this is
covered by the national health scheme. However, the cost for
monitoring HBV-DNA is not included in the national AIDSAIDS Research and Treatment 5
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Figure 1: Treatment scheme for HCV coinfection guided by genotype and HCV-RNA load assessment at baseline, wks 4, 12, and 24
[48, 72].∗Patients having baseline HCV-RNA load <400,000IU/mL with minimal ﬁbrosis.
program, and the patients have to pay for this by themselves.
Other nucleoside analogs such as adefovir, telbivudine, and
entecavir are also not included because the government
has decided that these drugs are not essential for the mass
treatment of HBV. Moreover, it is still unclear which HBV
drugs should be used for the preferred regimen in pregnant
women, and infants born to HBV co-infected mothers.
The situation is even worse for those co-infected with
HIV and HCV. The current national treatment guideline
recommends pegylated interferon α2a or 2b plus ribavirin
(Figure 1). Pegylated interferon and ribavirin are not on
WHO and Asian national essential medicines lists for all
HCV patients and hence are not freely provided through
the national health schemes. As for other low and middle-
income countries, many patients cannot aﬀord pegylated
interferon and ribavirin due to its costs. Currently, patented
pegylated interferon from Roche (Pegasys) and Merck
(PegIntron) is packaged and sold with generic ribavirin.
Because of these patents, hepatitis C treatment remains
to be expensive. For a 48-week treatment course, it costs
approximately $26,000–30,000 USD. Thus, most health care
systems cannot provide treatment for HCV and will refuse
to oﬀer treatment to majority of patients with HCV. This
price does not include other related investigations such as
HCV genotyping and HCVRNA as well as treatment for
unexpected complications. HCV RNA should be assessed
before commencing treatment and used to assess the eﬃcacy
of the treatment regimen. The most common adverse events
are neuropsychiatric symptoms and marrow toxicity which
can add to the cost of treatment and contribute to premature
treatment termination. Therefore, in order to minimize
adverse eﬀects, antiretroviral therapy needs to be adjusted.
Concomitant use of zidovudine is contraindicated due to
its eﬀect on the bone marrow; bone marrow suppression is
worsened by the use of zidovudine. The use of didanosine
is also not recommended during HCV therapy due to
increased risks of hepatic decompensation. Problems are
further exacerbated if the patient is co-infected with HCV
and HIV and receiving treatment concomitantly. It is not
possible for all HCV/HIV co-infected patients to get HCV
treatment because it is very expensive and has several
intolerable side eﬀects. Patients on ART also suﬀer from pill
burdens and side eﬀects of antiretroviral drugs.
Asaresultofthis,imagesoftheliverbyusingultrasound,
levels of serum aminotransaminase, and α-fetoprotein are
regularlymonitoredinHCVco-infectedpatients(seeTable 2
for summary). Liver biopsy is rarely done to avoid com-
plications and risks for contamination, especially in HIV-
infected treatment-na¨ ıve patients. Most Thai patients with
HCVinfectionhavegenotype3,thetypewhichrespondswell
to treatment, allowing physicians to reduce the treatment
duration to 12–16 weeks in those achieving rapid virological
response (RVR); this is based on the ﬁndings that 82%
of patients were successfully treated for HCV which is
comparable to a 24-week treatment course [57] and is still
also cost-eﬀective if retreating the cases with relapses for
24 weeks [58]. During treatment, RVR measured at week
4 is a strong predictor of sustained virological response
(SVR) [59]. Because of this, short-course treatment for 24
weeksisrecommendedtothepatientsinfectedwithgenotype
2/3, and a shorter treatment course (12–16 weeks) may be
an option for patients unable to tolerate treatment with
close RVR monitoring. The response-guided therapy aims
tooptimizetreatmentoutcomeswithoutcompromisingSVR
rates [60].
IL28B gene polymorphisms modulate early virological
response to peginterferon/ribavirin treatment and is associ-
ated with SVR in patients infected with genotype 2/3 HCV
who did not achieve RVR [61]. The favorable CC genotype,
as compared to either the CT or TT genotypes, has been
associated with a 3-fold increase in the rate for spontaneous
clearance of HCV [62] and 2-3 folds higher rate of SVR6 AIDS Research and Treatment
Table 2: Summary of diagnostic criteria and treatment currently in use as well as its perspectives in management.
Stage of disease Diagnostic criteria Current treatment
practices Perspectives in management
Chronic
hepatitis B
coinfection
(i) HBsAg+ >6m o s
(ii) Serum HBV DNA >2,000IU/mL (104
copies/mL)
(iii) Persistent or intermittent ALT/AST elevation
(iv) Liver biopsy (done in some) showing chronic
hepatitis with moderate or severe
necroinﬂammation
Tenofovir plus
lamivudine or tenofovir
plus emtricitabine
(i) HBV-DNA assessment for treatment
outcome
(ii) Add adefovir or entecavir if no virologic
suppression or suspected resistance
(iii) Close monitoring of cirrhosis and
hepatocellular carcinoma
(iv) Hepatitis B vaccination for susceptible
partner
Inactive HBsAg
carrier state
among PLWHA
(i) HBsAg+ >6m o s
(ii) HBeAg−, anti-HBe+
(iii) Serum HBV DNA <2,000IU/mL (104
copies/mL)
(iv) Persistently normal ALT/AST levels
(v) Liver biopsy (unfortunately not done in
clinical practice as recommended) conﬁrms
absence of signiﬁcant hepatitis
Due to limited options
of antiretroviral
regimen, lamivudine is
used as part of HAART
in majority of cases that
need HIV treatment
(i) Misleading term/new term “chronic low
replicative hepatitis B” can be used
(ii) Lamivudine/emtricitabine preserved for
combination treatment for HBV infection if
indicated
(iii) Need to closely F/U: LFT. α-FP and
ultrasound regularly at least q 6–12 mos for
cirrhotic patients
(iv) Hepatitis B vaccination for susceptible
partner
Occult hepatitis
B coinfection or
isolated core
antibody
(i) Presence of anti-HBc +/− anti-HBs
(ii) HBsAg−
(iii) Undetectable serum HBV DNA (very low
levels may be detected by sensitive PCR assays) or
serum HBV DNA <2,000IU/mL (104 copies/mL)
(iv) Normal ALT levels
Due to limited options
of antiretroviral
regimen, lamivudine is
used as part of HAART
in majority of cases that
need HIV treatment
(i) Lamivudine/emtricitabine preserved for
combination treatment for future HBV
infection if occult infection suspected
(ii) LFT q 6 mos if ALT/AST elevated, further
assessment for HBe Ag and HBV-DNA
(iii) Hepatitis B vaccination for susceptible
partner
(iv) It is not clear whether Hepatitis B
revaccination is needed or not
Chronic
hepatitis C
coinfection
(i) Anti-HCV+ and HCV-RNA+
(ii) Normal ALT levels or ALT elevation
(iii) Liver biopsy showing ﬁbrosis (or Fibroscan
>7.5kPa)
No treatment in most
cases
For those who can aﬀord
treatment: PegIFNα2a or
2b plus ribavirin
800mg/D, duration of
treatment guided by
genotype: 3,6 for 24 wks;
1f o r4 8w k s
(i) Selected cases with good prognostic factors
can access treatment comprising PegIFN plus
RBV
(ii) Genotyping and HCV-RNA for assessing
EVR, RVR, and SVR
(iii) Lower dose of PegIFN
(iv) Shorter treatment duration
(v) Need F/U: LFT, α-FP and ultrasound q
6–12 mos for cirrhotic patients
(vi) Close monitoring of cirrhosis and HCC
(vii) Harm reduction to reduce transmission
in HCV genotype 1 chronically infected individuals treated
with combination pegylated interferon/ribavirin therapy
[63]. In contrast to HCV genotype 1 patients, despite the
faster initial viral response in the patients carrying C/C,
SVR rates of mono-HCV genotype 3 infection were not
diﬀerent compared to the patients carrying T-allele [64, 65].
Quantitative evaluation of interferon-γ-inducible protein-
10 (IP-10) may add on the predictive value of IL28B
polymorphisms for HCV treatment responses [66]. The
clinical outcomes of an earlier viral decline and a shorter
course treatment in CC patients infected with HIV/HCV
genotype2/3arewarranted.Nonetheless,accesstotreatment
in Thailand is still hindered by the costs of the medications.
Furthermore, drug toxicities may contribute to incomplete
treatment for HCV among HIV-infected individuals. In
ordertosustaintheeﬀectivenessofHCVtreatment,evidence
baseinformationonepidemiologyandIL28Bpolymorphism
in speciﬁc population can be used to minimize the duration
of treatment but may compromise the cost instead. There-
fore, policy makers need to strongly reconsider integrating
optimized treatment regimen for HCV co-infection into the
national program for the future.
5. Prevention Programs
After successful integration of the national expanded pro-
gram on immunization (EPI) on HBV immunization, cov-
erage of the vaccinations has increased in most countries
up to 80% as seen by the results from many studies on
incidence reduction of HBV and hepatocellular carcinoma
in the young age group [68–72]. Due to the high prevalence
of HBV infection in the region, HBV serology screening
prior to vaccination in high risk groups is not necessary, for
example, MSMs, IDUs, and health care workers (HCWs).AIDS Research and Treatment 7
Many adults, including health care workers (HCWs), cannot
reimburse for HBV vaccinations. Currently, the guideline
recommendation for HBV treatment and care for HCWs is
notwelldeﬁned.Ifpeopleareawareofthecomplicationsand
prognosis of chronic hepatitis, this may encourage people
to have HBV serology screening and HBV vaccinations in
adults older than 30 years old. For postexposure prophylaxis,
hepatitis B immunoglobulin (HBIG) is required in cases that
have been exposed to blood from HBV-infected individuals
and are not immune to HBV according to the postexposure
HBV screening test. Occupational risks can be prevented if
high risk groups such as HCWs and health-related students
have been immunized. This preventive policy targeting
professional health care workers (i.e., hospitals and clinics)
at risk of acquiring HBV infection should be integrated
into the national health care system. Currently, HBV immu-
nization is recommended to all HIV-infected patients who
are susceptible and have achieved immunological success
after antiretroviral therapy. However, it is important to
conduct a serologic test for HBV to conﬁrm the person’s
immune status before vaccination because low CD4 levels
or the use of NNRTI may aﬀect the response to the vaccine
[67]. It has been shown that in HIV-infected individuals,
the immune response of generating HBs antibodies was
71.4% which was much lower compared to healthy HIV
seronegativeindividuals.However,noadverseeventhasbeen
detected.
Since HCV vaccines are not available for the prevention
of the disease, hence it is essential for all high risk groups,
including MSMs and IDUs, to continuously receive updated
information on HCV transmission and outcomes to reduce
their behavior risk of blood-to-blood contamination. Lack
of free access to clean injecting equipment for IDUs may not
be a critical issue because syringes and needles are available
cheaplyindrugstores.However,duetosocialstigmatization,
discrimination, and illegal issues, IDUs are afraid to access
clean needles and syringes resulting in higher rates of HIV
and HCV infection. Even though the Needle and Syringe
Program, a harm reduction eﬀort, is successful in Australia
inpreventingHCVandHIVinfectionamongIDUs,butsuch
a program is diﬃcult to launch in resource-limited setting
with a conservative society. Hence, continuing education
and health promotion are required to provide correct
information to the community to change their perception
as a preventive strategy. HIV/HCV co-infection among IDUs
is a public health emergency that is currently being ignored
by the policy makers. The need for proper policy and
advocacy are needed and should be presented through health
promotion campaigns in collaboration with working groups
and peer educators to successfully implement and launch
harm reduction programs properly. Community advocates
and appropriate waste disposal need to be worked out before
rolling out the harm reduction programs. Regular HCV
screening for high risk groups, especially HCWs and patients
with chronic renal failure on hemodialysis, is necessary.
Voluntarily unpaid donor blood must be routinely screened
for HBV and HCV serology at every blood bank unit
throughout the region as currently being performed by the
Red Cross blood banks.
6. Perspectiveson HepatitisB andC
Coinfection among HIV-Infected Patients for
Testing andTreatment
Since HBV co-infection is more chronic, therefore the
national guidelines have recommended suﬃcient and early
screening to initiate proper treatment and care. Despite
this, there are still problems for those patients who have
developed resistance and have limited selection of drugs to
choose from and/or intolerability. It will be a continued
struggle to provide alternative treatment and other drug
choices for these patients. Hepatitis B vaccination should
be implemented at all levels of the population, especially
high risk groups and health care workers; HBV vaccination
is an urgent and necessary action that should be in place
in order to reduce HBV infection. The strategic plan must
cover adults older than 30 years old who may become
infected and transmit the virus to others via the sexual route.
Hepatitis B is preventable and immunization is better than
acquiring the virus. The cost of the immunization program
is incomparable to the people’s quality of life. Recently 2 new
protease inhibitors, boceprevir and telaprevir, were approved
by the US FDA in May 2011 and by the European Medicine
Agency (EMA) in August and September 2011, respectively,
for HCV treatment. The drugs can increase the eﬃcacy and
RVR when used as a triple drug therapy (with pegylated
interferon and ribavirin) in HCV patients with genotype 1
[73–77], but the cost is 2-3 times higher than the standard
treatment. For these new drugs, the US FDA is concerned
about the adverse events such as suicidal tendencies and
lack of eﬃcacy in certain groups of people; boceprevir has
been shown to cause rash and gout whereas telaprevir has
been associated with TB. Both boceprevir and telaprevir
can cause anemia in HCV patients. However, it should be
noted that anemia is a common laboratory abnormality
among patients infected with both HIV and HCV due to
treatment; physicians will need to reduce the dose of their
HCV medications in patients with anemia [78]. Aside from
additional drug toxicities, evidence-based information from
monoinfected HCV clinical trials on shorter triple drug
treatment, pharmacokinetics guided optimized dose of new
drugs, and potential drug-drug interactions warrant further
investigations in Asian population living with HIV/AIDS.
HCV Direct-Acting Antivirals (DAAs), new polymerase and
protease inhibitors that are under clinical investigations with
or without interferon, provide HCV patients with more
treatment options. Quad therapy (2 diﬀerent protease
inhibitors plus pegylated interferon and ribavirin) is another
option that will become available in the future regardless of
the cost of the drugs. To improve tolerability and treatment
coverage, the interferon-free DAA-based combination ther-
apy may be an alternative choice for some people [79].
HCV infection is a curable disease and the international
clinical guidelines already have provided recommendations
for screening, diagnostics, and treatment for HCV/HIV co-
infected patients. Yet majority of the patients, especially
IDUs co-infected with HIV and HCV, still have problems
in getting the proper treatment and care. The social stigma
around drug use pervades many aspects of the society,8 AIDS Research and Treatment
creating huge barriers that IDUs face when seeking health
care. The barriers in the health care setting, including preju-
dice and stigmatization, are worse than HIV monoinfection
becausethemedicalserviceprovidersandpolicymakershave
insuﬃcient experience in dealing with co-infected patients
resulting in limited care and ﬁnancial support. Physicians
may refuse treatment to IDUs because of their perceptions
that these patients have poor adherence to treatment. In fact,
treatment adherence among IDUs substantially increased
when they have access to health and social services with
harm reduction support and mental health care. A challenge
can be met through educating medical staﬀ and providing
support for patients. Access to treatment and healthcare
should be abrogated by national policymakers when it comes
to treating HCV in HIV co-infected patients. The main
economic beneﬁt to treating people with HCV is that it will
lower the cost and amount of medical care needed for HCV
in the long term, including treatment for severe liver disease
and HCV-related liver malignancy. Moreover, it is absolutely
impossible to put a price on the patient’s quality of life as
it is priceless and invaluable. Successful treatment can also
prevent new HCV infections.
Acknowledgments
All authors declare no aﬃliations or ﬁnancial involvement
with any organization or entity with a ﬁnancial interest in
or ﬁnancial conﬂict with the subject matter or materials
discussed in the paper apart from those disclosed. The
authors would like to thank the Australasian Society for HIV
Medicine (ASHM) and ASHM-AusAID ALAF Training Pro-
gram on HIV and Viral Hepatitis Co-infection Management
in Asia for inspiring us to write the paper.
References
[1] S. Vong, J. F. Perz, S. Sok et al., “Rapid assessment of injection
practices in Cambodia, 2002,” BMC Public Health, vol. 5,
article 56, 2005.
[2] H. T. T. Tran, H. Ushijima, V. X. Quang et al., “Prevalence of
hepatitis virus types B through E and genotypic distribution
of HBV and HCV in Ho Chi Minh City, Vietnam,” Hepatology
Research, vol. 26, no. 4, pp. 275–280, 2003.
[3] P. Jutavijittum, A. Yousukh, B. Samountry et al., “Seropreva-
lence of hepatitis B and C virus infections among Lao blood
donors,” Southeast Asian Journal of Tropical Medicine and
Public Health, vol. 38, no. 4, pp. 674–679, 2007.
[4] V.Wiwanitkit,“AnoverviewofahepatitisBserologyscreening
check-up program among Thai workers,” Viral Immunology,
vol. 15, no. 4, pp. 647–649, 2002.
[5] E. J. Nelwan, R. Van Crevel, B. Alisjahbana et al., “Human
immunodeﬁciency virus, hepatitis B and hepatitis C in an In-
donesian prison: prevalence, risk factors and implications of
HIV screening,” Tropical Medicine and International Health,
vol. 15, no. 12, pp. 1491–1498, 2010.
[6] Y. Yanase, T. Ohida, Y. Kaneita, D. M. D. Agdamag, P. S.
A. Lea˜ no, and C. J. Gill, “The prevalence of HIV, HBV and
HCV among Filipino blood donors and overseas work visa
applicants,” Bulletin of the World Health Organization, vol. 85,
no. 2, pp. 131–137, 2007.
[7] V .J .Sebastian,S.B hattac hary a,S.Ra y ,andJ .H.Daud,“P r eva-
lence of hepatitis-B surface antigen in the pregnant women of
Brunei Darussalam,” The Southeast Asian Journal of Tropical
Medicine and Public Health, vol. 21, no. 1, pp. 123–127, 1990.
[8] M. J. Alexander, A. S. Sinnatamby, M. J. Rohaimah, A. H.
Harun, and J. S. Ng, “Incidence of hepatitis B infection in
Brunei Darussalam–analysis of racial distribution,” Annals of
the Academy of Medicine Singapore, vol. 19, no. 3, pp. 344–346,
1990.
[9] P. Luksamijarulkul, W. Kaepan, and S. Klamphakorn, “Hep-
atitis B virus sero-markers, hepatitis C virus antibody and risk
behaviors among middle age and older Thai males,” Southeast
Asian Journal of Tropical Medicine and Public Health, vol. 38,
no. 1, pp. 45–52, 2007.
[10] S. Sungkanuparph, A. Vibhagool, W. Manosuthi et al., “Preva-
lence of hepatitis B virus and hepatitis C virus co-infection
with human immunodeﬁciency virus in Thai patients: a
tertiary-care-based study,” Journal of the Medical Association
of Thailand, vol. 87, no. 11, pp. 1349–1354, 2004.
[11] W. P. Law, G. J. Dore, C. J. Duncombe et al., “Risk of severe
hepatotoxicity associated with antiretroviral therapy in the
HIV-NATCohort,Thailand,1996-2001,”AIDS,vol.17,no.15,
pp. 2191–2199, 2003.
[12] S. Kiertiburanakul, D. Chotiprasitsakul, K. Atamasirikul, and
S. Sungkanuparph, “Late and low compliance with hepatitis B
serologyscreeningamongHIV-infectedpatientsinaresource-
limited setting: an issue to improve HIV care,” Current HIV
Research, vol. 9, no. 1, pp. 54–60, 2011.
[13] S. Sungkanuparph, P. Wongprasit, W. Manosuthi, and K.
Atamasirikul, “Compliance with hepatitis B and hepatitis C
virus infection screening among HIV-1 infected patients in a
resource-limited setting.,” The Southeast Asian Journal of Tro-
pical Medicine and Public Health, vol. 39, no. 5, pp. 863–866,
2008.
[14] N. S. W. Leeratanapetch, “Hepatitis B virus and hepatitis C
virus co-infection with HIV patients at Khon Kaen Hospital,”
Khon Kaen Hospital Medical Journal, vol. 32, no. 2, pp. 229–
238, 2008.
[15] A. Theamboonlers, P. Tangkijvanich, C. Pramoolsinsap, and
Y. Poovorawan, “Genotypes and subtypes of hepatitis B virus
in Thailand,” Southeast Asian Journal of Tropical Medicine and
Public Health, vol. 29, no. 4, pp. 786–791, 1998.
[16] A. Theamboonlers, P. Jantaradsamee, N. Kaew-In, P. Tangk-
ijvanich, P. Hirsch, and Y. Poovorawan, “The predominant
genotypes of hepatitis B virus in Thailand,” Annals of Tropical
Medicine and Parasitology, vol. 93, no. 7, pp. 737–743, 1999.
[17] P. Tangkijvanich, V. Mahachai, P. Komolmit, J. Fongsarun,
A. Theamboonlers, and Y. Poovorawan, “Hepatitis B virus
genotypes and hepatocellular carcinoma in Thailand,” World
Journal of Gastroenterology, vol. 11, no. 15, pp. 2238–2243,
2005.
[18] A. Utama, S. Purwantomo, M. D. Siburian et al., “Hepatitis
B virus subgenotypes and basal core promoter mutations in
Indonesia,” World Journal of Gastroenterology, vol. 15, no. 32,
pp. 4028–4036, 2009.
[19] A. Utama, T. I. Octavia, R. Dhenni, U. A. Miskad, I. Yusuf, and
S.Tai,“HepatitisBvirusgenotypes/subgenotypesinvoluntary
blood donors in Makassar, South Sulawesi, Indonesia,” Virol-
ogy Journal, vol. 6, article 128, 2009.
[20] P.Sa-nguanmoo,P.Tangkijvanich,N.Thawornsuketal.,“Mo-
lecular epidemiological study of hepatitis B virus among mi-
grant workers from Cambodia, Laos, and Myanmar to Thai-
land,” Journal of Medical Virology, vol. 82, no. 8, pp. 1341–
1349, 2010.AIDS Research and Treatment 9
[21] K. Suwannakarn, P. Tangkijvanich, N. Thawornsuk et al.,
“Molecular epidemiological study of hepatitis B virus in Thai-
land based on the analysis of pre-S and S genes,” Hepatology
Research, vol. 38, no. 3, pp. 244–251, 2008.
[22] W. Jilg, C. Delhoune, and F. Deinhardt, “Hepatitis B surface
antigen (HBsAg) subtype-speciﬁc antibodies in persons vacci-
nated against hepatitis B,” Journal of Medical Virology, vol. 13,
no. 2, pp. 171–178, 1984.
[23] V.M.Quan,V.F.Go,L.V.Nametal.,“RisksforHIV,HBV,and
HCV infections among male injection drug users in northern
Vietnam: a case-control study,” AIDS Care,v o l .2 1 ,n o .1 ,p p .
7–16, 2009.
[24] A. Jatapai, K. E. Nelson, T. Chuenchitra et al., “Prevalence and
risk factors for hepatitis C virus infection among young Thai
men,” American Journal of Tropical Medicine and Hygiene, vol.
83, no. 2, pp. 433–439, 2010.
[25] T. Tanimoto, N. H. Cuong, A. Ishizaki et al., “Multiple routes
of hepatitis C virus transmission among injection drug users
inHaiPhong,NorthernVietnam,”JournalofMedicalVirology,
vol. 82, no. 8, pp. 1355–1363, 2010.
[ 2 6 ] S .K a g e y a m a ,D .M .D .A g d a m a g ,E .T .A l e s n ae ta l . ,“ T r a c k i n g
the entry routes of hepatitis C virus as a surrogate of HIV in
an HIV-low prevalence country, the Philippines,” Journal of
Medical Virology, vol. 81, no. 7, pp. 1157–1162, 2009.
[27] D. J. Jamieson, N. Skunodom, T. Chaowanachan et al., “Infec-
tion with hepatitis C virus among HIV-infected pregnant
women in Thailand,” Infectious Diseases in Obstetrics and Gy-
necology, vol. 2008, Article ID 840948, 7 pages, 2008.
[28] S. Akkarathamrongsin, K. Praianantathavorn, N. Hacharoen
et al., “Geographic distribution of hepatitis C virus genotype
6 subtypes in Thailand,” Journal of Medical Virology, vol. 82,
no. 2, pp. 257–262, 2010.
[29] A. Utama, N. P. Tania, R. Dhenni et al., “Genotype diversity
of hepatitis C virus (HCV) in HCV-associated liver disease
patients in Indonesia,” Liver International,v o l .3 0 ,n o .8 ,p p .
1152–1160, 2010.
[30] S. Akkarathamrongsin, K. Praianantathavorn, N. Hacharoen,
A. Theamboonlers, P. Tangkijvanich, and Y. Poovorawan,
“Seroprevalence and genotype of Hepatitis C virus among im-
migrant workers from Cambodia and Myanmar in Thailand,”
Intervirology, vol. 54, no. 1, pp. 10–16, 2010.
[31] J. F. Colin, D. Cazals-Hatem, M. A. Loriot et al., “Inﬂuence of
humanimmunodeﬁciencyvirusinfectiononchronichepatitis
Bi nh o m o s e x u a lm e n , ”Hepatology, vol. 29, no. 4, pp. 1306–
1310, 1999.
[32] V. Di Martino, T. Thevenot, J. F. Colin et al., “Inﬂuence of HIV
infection on the response to interferon therapy and the long-
term outcome of chronic hepatitis B,” Gastroenterology, vol.
123, no. 6, pp. 1812–1822, 2002.
[33] C. L. Thio, E. C. Seaberg, R. Skolasky Jr. et al., “HIV-1,
hepatitis B virus, and risk of liver-related mortality in the
MulticenterCohortStudy(MACS),”Lancet,vol.360,no.9349,
pp. 1921–1926, 2002.
[34] G. M. Cliﬀord, M. Rickenbach, J. Polesel et al., “Inﬂuence of
HIV-related immunodeﬁciency on the risk of hepatocellular
carcinoma,” AIDS, vol. 22, no. 16, pp. 2135–2141, 2008.
[35] D. W. P. Chotiprasitsakul, K. Atamasirikul, and S. Sungkanu-
parph, “Screening of hepatitis B virus infection among HIV
infected patients receiving antiretroviral therapy,” Journal of
Infectious Diseases and Antimicrobial Agents,v o l .2 7 ,n o .2 ,p p .
69–75, 2010.
[36] J. Zhou, G. J. Dore, F. Zhang, P. L. Lim, and Y. M. A. Chen,
“Hepatitis B and C virus coinfection in the TREAT Asia
HIV Observational Database,” Journal of Gastroenterology and
Hepatology, vol. 22, no. 9, pp. 1510–1518, 2007.
[37] Y. Jongjirawisan, P. Ungulkraiwit, and S. Sungkanuparph,
“Isolated antibody to hepatitis B core antigen in HIV-1 in-
fected patients and a pilot study of vaccination to determine
the anamnestic response,” Journal of the Medical Association of
Thailand, vol. 89, no. 12, pp. 2028–2034, 2006.
[38] C. C. Hung, C. F. Hsiao, R. T. Gandhi, B. McGovern, H. Lee,
and P. Sax, “Isolated Antibody to Hepatitis B Core Antigen in
Individuals Infected with HIV-1,” Clinical Infectious Diseases,
vol. 37, no. 9, pp. 1275–1277, 2003.
[39] D. Neau, M. Winnock, A. C. Jouvencel et al., “Occult hepatitis
B virus infection in HIV-infected patients with isolated anti-
bodies to hepatitis B core antigen: aquitaine cohort, 2002-
2003,” Clinical Infectious Diseases, vol. 40, no. 5, pp. 750–753,
2005.
[40] R. T. Gandhi, A. Wurcel, H. Lee et al., “Isolated antibody to
hepatitis B core antigen in human immunodeﬁciency virus
type-1-infected individuals,” Clinical Infectious Diseases, vol.
36, no. 12, pp. 1602–1605, 2003.
[41] A.L.French,M.Y.Lin,C.T.Evansetal.,“Long-termserologic
follow-up of isolated hepatitis b core antibody in hiv-infected
and hiv-uninfected women,” Clinical Infectious Diseases, vol.
49, no. 1, pp. 148–154, 2009.
[ 4 2 ]A .E d u a r d eS i l v a ,B .J .M c M a h o n ,A .J .P a r k i n s o n ,M .H .
Sjogren, J. H. Hoofnagle, and A. M. Di Bisceglie, “Hepatitis
B virus DNA in persons with isolated antibody to hepatitis B
core antigen who subsequently received hepatitis B vaccine,”
Clinical Infectious Diseases, vol. 26, no. 4, pp. 895–897, 1998.
[43] M. Hofer, H. I. Joller-Jemelka, P. J. Grob, R. L¨ uthy, and M.
Opravil, “Frequent chronic hepatitis B virus infection in HIV-
infected patients positive for antibody to hepatitis B core anti-
gen only,” European Journal of Clinical Microbiology and In-
fectious Diseases, vol. 17, no. 1, pp. 6–13, 1998.
[44] H. T. Chung, J. S. K. Lee, and A. S. F. Lok, “Prevention of
posttransfusion hepatitis B and C by screening for antibody
to hepatitis C virus and antibody to HBcAg,” Hepatology, vol.
18, no. 5, pp. 1045–1049, 1993.
[45] R. C. Dickson, J. E. Everhart, J. R. Lake et al., “Transmission
of hepatitis B by transplantation of livers from donors positive
for antibody to hepatitis B core antigen,” Gastroenterology, vol.
113, no. 5, pp. 1668–1674, 1997.
[46] J. H. Hoofnagle, L. B. Seeﬀ, Z. B. Bales, and H. J. Zimmerman,
“Type B hepatitis after transfusion with blood containing
antibody to hepatitis B core antigen,” New England Journal of
Medicine, vol. 298, no. 25, pp. 1379–1383, 1978.
[47] M. N´ u˜ nez, P. R´ ıos, M. P´ erez-Olmeda, and V. Soriano, “Lack of
“occult” hepatitis B virus infection in HIV-infected patients,”
AIDS, vol. 16, no. 15, pp. 2099–2101, 2002.
[48] D. D. Douglas, H. F. Taswell, J. Rakela, and D. Rabe, “Absence
of hepatitis B virus DNA detected by polymerase chain re-
action in blood donors who are hepatitis B surface antigen
negativeandantibodytohepatitisBcoreantigenpositivefrom
a United States population with a low prevalence of hepatitis
B serologic markers,” Transfusion, vol. 33, no. 3, pp. 212–216,
1993.
[49] E. C. Thomson, E. Nastouli, J. Main et al., “Delayed anti-HCV
antibody response in HIV-positive men acutely infected with
HCV,” AIDS, vol. 23, no. 1, pp. 89–93, 2009.
[50] C. Scott, S. Day, E. Low, A. Sullivan, M. Atkins, and D. Asboe,
“Unselected hepatitis C screening of men who have sex with
men attending sexual health clinics,” Journal of Infection, vol.
60, no. 5, pp. 351–353, 2010.10 AIDS Research and Treatment
[51] Y. C. Gilleece, R. E. Browne, D. Asboe et al., “Transmission
of hepatitis C virus among HIV-positive homosexual men
and response to a 24-week course of pegylated interferon and
ribavirin,” Journal of Acquired Immune Deﬁciency Syndromes,
vol. 40, no. 1, pp. 41–46, 2005.
[52] V. Wiwanitkit, “Alpha fetoprotein for screening for hepatocel-
lular cancer in populations with viral hepatitis B: an appraisal
ofThaireports,”AsianPaciﬁcJournalofCancerPrevention,vol.
6, no. 4, pp. 535–536, 2005.
[53] P. Tangkijvanich, N. Anukulkarnkusol, P. Suwangool et al.,
“Clinical characteristics and prognosis of hepatocellular car-
cinoma: analysis based on serum alpha-fetoprotein levels,”
JournalofClinicalGastroenterology,vol.31,no.4,pp.302–308,
2000.
[54] A. Komindr, N. Praditphol, S. Suphanpayak et al., “Correla-
tion of HBV and HCV with CH, LC, HCC in liver biopsied
tissue at Rajavithi Hospital,” Journal of the Medical Association
of Thailand, vol. 88, no. 6, pp. 788–809, 2005.
[55] A. Avihingsanon, S. R. Lewin, S. Kerr et al., “Eﬃcacy of
tenofovir disoproxil fumarate/emtricitabine compared with
emtricitabine alone in antiretroviral-naive HIV-HBV coinfec-
tion in Thailand,” Antiviral Therapy, vol. 15, no. 6, pp. 917–
922, 2010.
[56] G. V. Matthews, A. Avihingsanon, S. R. Lewin et al., “A ran-
domized trial of combination hepatitis B therapy in HIV/HBV
coinfected antiretroviral na¨ ıve individuals in Thailand,” Hep-
atology, vol. 48, no. 4, pp. 1062–1069, 2008.
[ 5 7 ]S .S l a v e n b u r g ,I .W e g g e l a a r ,M .G .H .V a nO i j e n ,a n dJ .P .H .
Drenth, “Optimal length of antiviral therapy in patients with
hepatitis C virus genotypes 2 and 3: a meta-analysis,” Antiviral
Therapy, vol. 14, no. 8, pp. 1139–1148, 2009.
[58] A. K. Singal and B. S. Anand, “Tailoring treatment duration
to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid
virologic response: systematic review and meta-analysis of
randomized controlled trials,” Journal of Clinical Gastroen-
terology, vol. 44, no. 8, pp. 583–587, 2010.
[59] L. Martin-Carbonero, M. Nu˜ nez, A. Mari˜ no et al., “Unde-
tectable hepatitis C virus RNA at week 4 as predictor of sus-
tained virological response in HIV patients with chronic hep-
atitis C,” AIDS, vol. 22, no. 1, pp. 15–21, 2008.
[60] T. Berg and G. Carosi, “Optimizing outcomes in patients with
hepatitis C virus genotype 2 or 3,” Antiviral Therapy, vol. 13,
no. 1, pp. 17–22, 2008.
[61] A. Mangia, A. J. Thompson, R. Santoro et al., “An IL28B
polymorphism determines treatment response of hepatitis C
virus genotype 2 or 3 patients who do not achieve a rapid
virologic response,” Gastroenterology, vol. 139, no. 3, pp. 821–
827, 2010.
[ 6 2 ]D .L .T h o m a s ,C .L .T h i o ,M .P .M a r t i ne ta l . ,“ G e n e t i cv a r i a -
tion in IL28B and spontaneous clearance of hepatitis C virus,”
Nature, vol. 461, no. 7265, pp. 798–801, 2009.
[63] D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in
IL28B predicts hepatitis C treatment-induced viral clearance,”
Nature, vol. 461, no. 7262, pp. 399–401, 2009.
[64] T.-M. Scherzer, H. Hofer, A. F. Staettermayer et al., “Early
virologic response and IL28B polymorphisms in patients with
chronichepatitisCgenotype3treatedwithpeginterferonalfa-
2aandribavirin,”JournalofHepatology,vol.54,no.5,pp.866–
871, 2011.
[65] A. Moghaddam, E. Melum, N. Reinton et al., “IL28B genetic
variation and treatment response in patients with hepatitis C
virusgenotype3infection,”Hepatology,vol.53,no.3,pp.746–
754, 2011.
[66] J. M. Darling, J. Aerssens, G. Fanning et al., “Quantitation
of pretreatment serum interferon-γ-inducible protein-10 im-
proves the predictive value of an IL28B gene polymorphism
for hepatitis C treatment response,” Hepatology, vol. 53, no. 1,
pp. 14–22, 2011.
[67] M. L. Landrum, K. H. Hullsiek, A. Ganesan et al., “Hepatitis
B vaccine responses in a large U.S. military cohort of HIV-
infected individuals: another beneﬁt of HAART in those with
preserved CD4 count,” Vaccine, vol. 27, no. 34, pp. 4731–4738,
2009.
[68] K. Wichajarn, P. Kosalaraksa, and S. Wiangnon, “Incidence of
hepatocellular carcinoma in children in Khon Kaen before
and after national hepatitis B vaccine program,” Asian Paciﬁc
Journal of Cancer Prevention, vol. 9, no. 3, pp. 507–510, 2008.
[69] V. Chongsrisawat, P. Yoocharoen, A. Theamboonlers et al.,
“Hepatitis B seroprevalence in Thailand: 12 Years after hep-
atitis B vaccine integration into the national expanded pro-
gramme on immunization,” Tropical Medicine and Interna-
tional Health, vol. 11, no. 10, pp. 1496–1502, 2006.
[70] Y. Poovorawan, V. Chongsrisawat, A. Theamboonlers, H. L.
Bock, M. Leyssen, and J. M. Jacquet, “Persistence of antibodies
and immune memory to hepatitis B vaccine 20 years after in-
fant vaccination in Thailand,” Vaccine, vol. 28, no. 3, pp. 730–
736, 2010.
[71] Y. Poovorawan, V. Chongsrisawat, A. Theamboonlers et al.,
“EvidenceofprotectionagainstclinicalandchronichepatitisB
infection20yearsafterinfantvaccinationinahighendemicity
region,” Journal of Viral Hepatitis, vol. 18, no. 5, pp. 369–375,
2011.
[72] Y. Poovorawan, V. Chongsrisawat, A. Theamboonlers et al.,
“Long-term beneﬁt of hepatitis B vaccination among children
inThailandwithtransienthepatitisBvirusinfectionwhowere
born to hepatitis B surface antigen-positive mothers,” Journal
of Infectious Diseases, vol. 200, no. 1, pp. 33–38, 2009.
[73] F. Poordad, J. McCone Jr., B. R. Bacon et al., “Boceprevir for
untreated chronic HCV genotype 1 infection,” New England
Journal of Medicine, vol. 364, no. 13, pp. 1195–1206, 2011.
[74] B. R. Bacon, S. C. Gordon, E. Lawitz et al., “Boceprevir for
previously treated chronic HCV genotype 1 infection,” New
England Journal of Medicine, vol. 364, no. 13, pp. 1207–1217,
2011.
[75] J. G. McHutchison, M. P. Manns, A. J. Muir et al., “Telaprevir
for previously treated chronic HCV infection,” New England
Journal of Medicine, vol. 362, no. 14, pp. 1292–1303, 2010.
[76] J .G.M cH utchison,G.T .E verson,S.C.Gordonetal.,“T elapre-
vir with peginterferon and ribavirin for chronic HCV geno-
type 1 infection,” New England Journal of Medicine, vol. 360,
no. 18, pp. 1827–1838, 2009.
[77] K. E. Sherman, S. L. Flamm, N. H. Afdhal et al., “Response-
guided telaprevir combination treatment for hepatitis C virus
infection,” New England Journal of Medicine, vol. 365, no. 11,
pp. 1014–1024, 2011.
[78] P. Deming and I. R. McNicholl, “Coinfection with human
immunodeﬁciency virus and hepatitis C virus: challenges and
therapeutic advances—insights from the Society of Infectious
Diseases Pharmacists,” Pharmacotherapy,v o l .3 1 ,n o .4 ,p p .
357–368, 2011.
[ 7 9 ]G .J .D o r e ,G .V .M a t t h e w s ,a n dJ .R o c k s t r o h ,“ F u t u r eo f
hepatitis C therapy: development of direct-acting antivirals,”
Current Opinion in HIV and AIDS, vol. 6, no. 6, pp. 508–513,
2011.